Skip to main content

Table 2 Gout related treatment patterns overall and by presence of comorbidities

From: Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population

Gout-related medication Ever use during 1 year after gout diagnosis
  All No comorbidities
(n = 74,356)
Cardiometabolic§
(n = 64,385)
  Diabetes
(n = 26,818)
Chronic renal impairment
(n = 5,718)
ALL n % n % n % p-value* n % n %
NSAIDS 74,055 41.7% 32,701 44.0% 25,994 40.4% 0.022 9,592 35.8% 1,134 19.8%
selective 12,455 7.0% 4,102 5.5% 5,077 7.9% < .0001 1,942 7.2% 219 3.8%
nonselective 68,826 38.7% 31,167 41.9% 23,765 36.9% 0.173 8,660 32.3% 1,001 17.5%
Colchicine 29,686 16.7% 11,595 15.6% 11,327 17.6% < .0001 4,950 18.5% 1,559 27.3%
Corticosteroids 37,224 21.0% 14,182 19.1% 14,476 22.5% < .0001 5,153 19.2% 1,617 28.3%
Probenecid 2,510 1.4% 1,108 1.5% 901 1.4% 0.249 331 1.2% 58 1.0%
Allopurinol 56,544 31.8% 23,215 31.2% 20,971 32.6% < .0001 9,183 34.2% 2,512 43.9%
No treatment 69,241 39.0% 29,202 39.3% 24,938 38.7% < .0001 10,669 39.8% 2,171 38.0%
FEMALES N = 43,304 N = 12,387 N = 17,418   N = 9,381 N = 2,025
NSAIDS 16,183 37.4% 4,641 37.5% 6,464 37.1% < .0001 3,279 35.0% 368 18.2%
   selective 3,815 8.8% 911 7.4% 1,643 9.4% < .0001 769 8.2% 77 3.8%
   nonselective 14,423 33.3% 4,255 34.4% 5,684 32.6% 0.000 2,899 30.9% 320 15.8%
Colchicine 5,096 11.8% 890 7.2% 2,312 13.3% < .0001 1,558 16.6% 483 23.9%
Corticosteroids 9,831 22.7% 2,438 19.7% 4,213 24.2% < .0001 1,954 20.8% 575 28.4%
Probenecid 441 1.0% 96 0.8% 195 1.1% 0.359 115 1.2% 27 1.3%
Allopurinol 8,905 20.6% 1,676 13.5% 4,006 23.0% < .0001 2,692 28.7% 834 41.2%
No treatment 19,637 45.3% 6,200 50.1% 7,693 44.2% < .0001 3,991 42.5% 816 40.3%
MALES N = 134,333 N = 61,969 N = 46,967   N = 17,437 N = 3,693
NSAIDS 57,872 43.1% 28,060 45.3% 19,530 41.6% 0.575 6,313 36.2% 766 20.7%
   selective 8,640 6.4% 3,191 5.1% 3,434 7.3% < .0001 1,173 6.7% 142 3.8%
   nonselective 54,403 40.5% 26,912 43.4% 18,081 38.5% 0.012 5,761 33.0% 681 18.4%
Colchicine 24,590 18.3% 10,705 17.3% 9,015 19.2% < .0001 3,392 19.5% 1,076 29.1%
Corticosteroids 27,393 20.4% 11,744 19.0% 10,263 21.9% < .0001 3,199 18.3% 1,042 28.2%
Probenecid 2,069 1.5% 1,012 1.6% 706 1.5% 0.260 216 1.2% 31 0.8%
Allopurinol 47,639 35.5% 21,539 34.8% 16,965 36.1% < .0001 6,491 37.2% 1,678 45.4%
No treatment 49,604 36.9% 23,002 37.1% 17,245 36.7% < .0001 6,678 38.3% 1,355 36.7%
  1. § Cardiometabolic disease include congestive heart failure, ischaemic heart disease, hypertension, cerebrovascular disease, peripheral arterial disease, dyslipidemia.
  2. * P-value from logistic model with drug as outcome associated to cardiometabolic comorbidities vs no comorbidities adjusting for age in categories (20-49, 50-59, 60-69, 70-79, 80-89).